## SUPPLEMENTARY FIGURES



**Supplementary Figure 1**. **Examine the protein expression of the galectin family in Huh-7 and Huh-7/SR cells.** Protein expression of the galectin family (Galectin-1, -2, -3, -4, -7, -8, and -9) in Huh-7 and Huh-7/SR cells was analyzed by Western blotting.



**Supplementary Figure 2. Overexpression of Galectin-1 enhances sorafenib resistance in HCC cells.** qRT-PCR and Western blotting analysis detected Galectin-1 (A) mRNA and (B) protein expression in HepG2 cells after Galectin-1 overexpression. (B) Cell viability of the indicated cells was measured using an MTT assay. Data are presented as means  $\pm$  standard deviations. \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001 (Student's *t* test).



Supplementary Figure 3. Inhibition of Galectin-1 reduced sorafenib resistance in HCC cells. (A) qRT-PCR analysis detected Galectin-1 mRNA expression in Mahlavu cells after Galectin-1 knockdown. (B) Cell viability of the indicated cells was measured using an MTT assay. Data are presented as means  $\pm$  standard deviations. \*P < 0.05, \*\*P < 0.01, and \*\*\*P < 0.001 (Student's t test).



**Supplementary Figure 4**. Knockdown of AXL and MET abolished Galectin-1 overexpression-induced sorafenib resistance. Cell viability after knockdown of (A) AXL and (B) MET in Huh-7/Gal cells treated with sorafenib for 48 h was measured using the MTT assay. Data are presented as means  $\pm$  standard deviations. \**P* < 0.05, \*\**P* < 0.01, and \*\*\**P* < 0.001 (Student's t test).



**Supplementary Figure 5. MET and AXL reduced sorafenib resistance in HCC cells.** (A) Galectin-1 was positively correlated with AXL in patients with HCC. (B) High Galectin-1 and MET expression were correlated with poor overall survival in patients with HCC. (C) High Galectin-1 and AXL expression was correlated with poor overall survival in patients with HCC.